Known Mutation-PD NeuroX samples (14.6%) still had more additional rare variants compared to No Known Mutation-PD (10.2%) and controls (9.0%), and ATP13A2 variants were still over-represented in LRRK2 G2019S carriers affected by PD. This evidence concerns the gene ATP13A2 and Parkinson disease.